癌症相关内脏静脉血栓的临床病史
国际前瞻性注册研究比较实体癌合并内脏静脉血栓(SVT)与常规部位静脉血栓栓塞(VTE)患者,各132例。SVT组转移性疾病和接受抗癌治疗比例较低,抗凝比例较低且疗程较短。两组12个月累积大出血、复发血栓和全因死亡率无显著差异。
要点
- 实体癌合并SVT患者转移性疾病和接受抗癌治疗比例低于常规部位VTE患者。
- SVT组抗凝比例68.9%低于常规VTE组99.2%,治疗时长6.0个月短于11.0个月。
- 两组12个月复发血栓、大出血和全因死亡率无显著差异。
核心结论
- 实体癌患者合并SVT与合并常规部位VTE的12个月复发血栓、大出血和全因死亡率相当。
研究设计与样本
- 国际前瞻性注册研究纳入2008年5月至2012年1月实体癌合并SVT患者,按1:1匹配两个血栓中心实体癌合并常规部位VTE患者,各132例,随访至少12个月。
主要发现
- SVT组转移性疾病比例36.1%低于常规VTE组72.5%,血栓诊断时接受抗癌治疗比例29.6%低于64.9%。
- SVT组最常见肿瘤为肝胆胰癌,常规VTE组最常见为胃肠道癌。
- SVT组抗凝比例68.9%低于常规VTE组99.2%,治疗时长6.0个月短于11.0个月。
- 12个月累积大出血SVT组2.3%对常规VTE组4.7%,差异无统计学意义。
- 12个月复发血栓SVT组4.7%对常规VTE组5.5%,全因死亡率41.7%对39.4%,两组相当。
临床怎么用
- 实体癌合并SVT患者的血栓复发和出血风险与常规部位VTE患者相似,可参考常规VTE管理思路。
局限性
- 需进一步前瞻性研究确认上述发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cancer represents a risk factor for splanchnic vein thrombosis (SVT) and usual site venous thromboembolism (VTE). OBJECTIVES: To compare characteristics and outcomes of patients with cancer-associated SVT and usual site VTE. PATIENTS/METHODS: Patients with solid cancer and SVT were enrolled in an international, prospective registry between May 2008 and January 2012. The comparison cohort included (1:1 ratio) patients with solid cancer and usual site VTE treated at two thrombosis centers who had a minimum of 12 months follow-up at December 2019 or experienced one of the outcomes within 12 months follow-up. Recurrent VTE, major bleeding, and all-cause mortality were evaluated at 12-month follow-up. RESULTS: A total of 264 patients (132 in each cohort) were enrolled. Patients with SVT were less likely to have metastatic disease (36.1% vs 72.5%) or receive cancer therapy at thrombosis diagnosis (29.6% vs 64.9%). The most frequent cancer types were hepatobiliary and pancreatic in the SVT cohort and gastrointestinal in the usual site VTE cohort. Fewer patients with SVT received anticoagulation (68.9% vs 99.2%), and treatment duration was shorter (6.0 vs 11.0 months). The cumulative incidence of major bleeding (2.3% vs 4.7%) was nonsignificantly lower in the SVT cohort, whereas recurrent thrombosis (4.7% vs 5.5%) and all-cause mortality (41.7% vs 39.4%) were comparable between the two cohorts. CONCLUSIONS: The risk of recurrent thrombosis and bleeding appears to be similar in cancer patients with SVT and cancer patients with usual site VTE, despite some differences in baseline characteristics and anticoagulant treatment. Further prospective studies are warranted to confirm these findings.
引用
- Valeriani E, Di Nisio M, Riva N, et al. Clinical history of cancer-associated splanchnic vein thrombosis. J Thromb Haemost. 2021. PMID: 33306241. doi:10.1111/jth.15214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。